Press release
Plaque Psoriasis Market Detailed Industry Report Analysis 2025-2034
Plaque Psoriasis Market
Plaque psoriasis is the most common type of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune skin disorder characterized by red, inflamed, and scaly plaques that significantly impair physical comfort, social interactions, and emotional well-being.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71345
Historically, treatments included topical corticosteroids, phototherapy, and systemic drugs. However, the market has been reshaped by the arrival of biologics, JAK/TYK2 inhibitors, and biosimilars, offering long-term efficacy and improved quality of life. With the growing prevalence of autoimmune diseases, patient advocacy, and expansion of personalized dermatology, the global plaque psoriasis market is poised for strong growth through 2034.
Market Overview
• Market Size 2024: USD 24 billion
• Forecast 2034: USD 37 billion
• CAGR (2025-2034): 5.1%
The plaque psoriasis market is expected to grow steadily, supported by adoption of IL-17 and IL-23 inhibitors, increasing use of small-molecule therapies, and affordability through biosimilars. Digital dermatology platforms and AI-based monitoring tools are further expanding patient engagement.
Leading Players include: AbbVie, Novartis, Eli Lilly, Johnson & Johnson, Amgen, Pfizer, Bristol Myers Squibb, UCB, and Sun Pharma.
Segmentation Analysis
By Product
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors)
• Small Molecules (JAK inhibitors, TYK2 inhibitors)
• Conventional Systemics (Methotrexate, Cyclosporine, Acitretin)
• Topical Agents (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Biosimilars
• Supportive Care Medications
By Platform
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
By Technology
• Biologic & Biosimilar Development Platforms
• JAK/TYK2 Inhibitor Development
• AI-Powered Dermatology & Digital Monitoring Tools
• Precision Medicine & Biomarker Diagnostics
By End Use
• Hospitals & Dermatology Clinics
• Specialty Immunology Centers
• Academic & Research Institutes
• Homecare Settings
By Application
• Mild Plaque Psoriasis
• Moderate Plaque Psoriasis
• Severe Plaque Psoriasis
Summary:
Biologics dominate the plaque psoriasis landscape, particularly IL-17 and IL-23 inhibitors, while TYK2 inhibitors represent the fastest-growing oral therapy class. Biosimilars are expanding affordability, especially in Europe and Asia-Pacific.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71345/plaque-psoriasis-market
Regional Analysis
North America
• Largest market with widespread adoption of biologics and TYK2 inhibitors.
• U.S. leads in FDA approvals, reimbursement support, and digital dermatology adoption.
Europe
• Strong presence with EMA-approved biologics and broad biosimilar adoption.
• Germany, France, and the UK remain leading contributors.
Asia-Pacific
• Fastest-growing region, supported by rising prevalence, healthcare investment, and biosimilar launches in China, India, and Japan.
Middle East & Africa
• Gradual growth as dermatology infrastructure improves, though biologic access remains limited due to affordability.
Latin America
• Moderate growth led by Brazil and Mexico, supported by increasing availability of biosimilars and biologics.
Regional Summary:
North America and Europe dominate the current market, while Asia-Pacific is projected to post the fastest CAGR through 2034, owing to demographics, healthcare expansion, and affordability of biosimilars.
Market Dynamics
Key Growth Drivers
• Rising global prevalence of plaque psoriasis and related comorbidities.
• Increasing adoption of biologics, JAK inhibitors, and TYK2 inhibitors.
• Biosimilar launches improving affordability worldwide.
• Digital health platforms enabling long-term patient engagement.
Key Challenges
• High costs of biologics and novel small molecules.
• Variability in treatment response and relapse risks.
• Limited specialist availability in low-income regions.
Latest Trends
• FDA/EMA approvals of IL-23 and TYK2 inhibitors.
• Growth of biosimilar competition in Europe and Asia.
• Expansion of teledermatology and AI-driven skin monitoring apps.
• Combination regimens under investigation for improved efficacy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71345
Competitor Analysis
Major Players in the Market:
• AbbVie - Leading with Humira and Skyrizi (IL-23 inhibitor).
• Novartis - Strong presence with Cosentyx (IL-17 inhibitor).
• Eli Lilly - Expanding share with Taltz (IL-17 inhibitor).
• Johnson & Johnson - Tremfya (IL-23 inhibitor) and Stelara (IL-12/23 inhibitor).
• Amgen - Strong in biosimilars and biologics.
• Pfizer - Expanding JAK/TYK2 inhibitor pipeline.
• Bristol Myers Squibb - Innovator with deucravacitinib (TYK2 inhibitor).
• UCB - Focused on dermatology biologics.
• Sun Pharma - Major generics and biosimilar supplier.
Competitive Dynamics:
The plaque psoriasis market is highly competitive, with AbbVie, Novartis, and Eli Lilly dominating biologics. BMS and Pfizer are driving momentum in small-molecule innovation, while biosimilar competition is reshaping affordability and access.
Conclusion
The plaque psoriasis market is undergoing significant transformation, driven by biologics, small molecules, and biosimilars. Despite affordability and access challenges, the market outlook through 2034 remains highly positive.
Key Takeaways:
• Market projected to grow at a CAGR of 5.1% (2025-2034).
• IL-17 and IL-23 inhibitors dominate, while TYK2 inhibitors are the fastest-growing.
• North America and Europe lead adoption, while Asia-Pacific is the fastest-growing region.
• Digital health platforms and biosimilars expand affordability and patient access.
• Competition is focused on biologics pipelines, biosimilar launches, and AI-driven dermatology tools.
Overall, the plaque psoriasis market presents strong opportunities for pharma leaders, biotech innovators, and healthcare providers to advance dermatology care and improve long-term patient outcomes.
This report is also available in the following languages : Japanese (プラーク乾癬市場), Korean (플라크 건선 시장), Chinese (斑块性银屑病市场), French (Marché du psoriasis en plaques), German (Markt für Plaque-Psoriasis), and Italian (Mercato della psoriasi a placche), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71345/plaque-psoriasis-market#request-a-sample
Our More Reports:
Actinic Keratosis Market
https://exactitudeconsultancy.com/reports/71368/actinic-keratosis-market
Androgenetic Alopecia Market
https://exactitudeconsultancy.com/reports/71370/androgenetic-alopecia-market
Bullous Pemphigoid Market
https://exactitudeconsultancy.com/reports/71372/bullous-pemphigoid-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis Market Detailed Industry Report Analysis 2025-2034 here
News-ID: 4163659 • Views: …
More Releases from Exactitude Consultancy
Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide.
Treatment approaches combine pharmacological agents, intrathecal therapies,…
Secondary Progressive Multiple Sclerosis Market to Set Phenomenal Growth From 20 …
Introduction
Secondary progressive multiple sclerosis (SPMS) is a chronic and often disabling phase of multiple sclerosis (MS), where patients transition from the relapsing-remitting stage to a steadily worsening neurological condition. SPMS leads to progressive disability, with symptoms such as muscle weakness, spasticity, mobility impairment, fatigue, and cognitive decline.
Historically, treatment options for SPMS were limited, focusing primarily on symptom management and supportive care. However, the past decade has brought disease-modifying therapies (DMTs)…
Primary Progressive Aphasia Market New Product Development & Latest Trends
Introduction
Primary progressive aphasia (PPA) is a rare neurodegenerative disorder characterized by the gradual loss of language abilities, including speaking, understanding, reading, and writing. Unlike other forms of aphasia caused by stroke or trauma, PPA arises from progressive damage to the brain's language centers, often associated with frontotemporal lobar degeneration (FTLD) or Alzheimer's disease pathology.
As awareness of PPA grows and diagnostic imaging advances, more cases are being identified. However, treatment remains…
Partial Paralysis Market Growth, Applications, Innovations and Business Outlook …
Introduction
Partial paralysis, also known as paresis, is a condition characterized by the loss of voluntary muscle control in certain parts of the body due to neurological, muscular, or traumatic causes. Unlike complete paralysis, patients retain some degree of movement and sensation, though often with significant limitations. The condition is commonly linked to stroke, spinal cord injury, multiple sclerosis (MS), cerebral palsy, traumatic brain injury, and neuropathies.
Partial paralysis poses major challenges…
More Releases for TYK2
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline 2025: FDA Updates, Therapy Innovati …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Emerging Trends Influencing The Growth Of The Kinase Inhibitors Market: Advances …
The Kinase Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Kinase Inhibitors Market Size Expected to Be by 2034?
The kinase inhibitors market will grow from $62.75 billion in 2024 to $67.57 billion in 2025, reflecting a CAGR of 7.7%. Growth…
TYK2 Kinase Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, …
(Albany, USA) "TYK2 Kinase Inhibitors Pipeline Insight, 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the TYK2 Kinase Inhibitors Therapeutics Market.
As per DelveInsight's assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the TYK2 Kinase Inhibitors pipeline landscape globally.
The TYK2 Kinase Inhibitors pipeline report provides a detailed description of the pipeline drugs, including the mechanism…
Key Trends Shaping the Future Kinase Inhibitors Market From 2025-2034: Advances …
What Is the Estimated Market Size and Growth Rate for the Kinase Inhibitors Market?
In the past few years, there has been a significant increase in the market size of kinase inhibitors. This market is set to expand from $62.75 billion in 2024 to $67.57 billion in 2025, marking a compound annual growth rate (CAGR) of 7.7%. The historical growth can be linked to numerous factors including the rise in cancer…
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Assessment, 2023 Updates | In-depth …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Non Receptor Tyrosine Protein Kinase TYK2 Market Share Will Gain Hugh Momentum b …
In recent years, the Global Non Receptor Tyrosine Protein Kinase TYK2 Market has witnessed significant growth and is expected to continue to do so during the forecast period 2023-2030. This report aims to provide a comprehensive analysis of the market's critical aspects, including its strengths, weaknesses, opportunities, and threats. With the help of SWOT and Porter's Five Forces analysis, we will explore the different players operating in the market and…
